# Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

> **NCT01114529** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 828 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Prograf or Neoral

## Key facts

- **NCT ID:** NCT01114529
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-09
- **Primary completion:** 2014-10-30
- **Final completion:** 2014-10-30
- **Target enrollment:** 828 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114529, "Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01114529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*